• 6 minuti fa

Categoria

🗞
Novità
Trascrizione
00:00When talking about primary biliary cholangitis, one must also consider the impact of symptoms such as itching and tiredness.
00:10chronic can have on the quality of life of people living with this autoimmune liver disease.
00:18Meanwhile, interesting long-term data from the Aschur study on the management of itching were presented at the congress.
00:30can you tell us about it?
00:31So yes, actually last week I would say numerous data were presented which demonstrate that even in the long term it means
00:4448 months with respect to the extremely important symptoms to consider and monitor.
00:51Here in the history of the management of this disease, for a very long time we have concentrated only on the ability to reduce
01:01the indicators of disease activity which are then surrogates in the sense that we do not only have an evident capacity to
01:10whether or not it was seen was judged only in terms of the ability to slow down or stop the progression of the disease.
01:20But biochemical surrogates were looked at, in particular alkaline phosphatase, indicators of cholestasis, that is, disease activity.
01:29Here it is the last one even knowing how these patients have a significant symptomatic procession, first of all the itching which is
01:40due to cholestasis i.e. the degree of activity of the disease correlates with the more cholestasis the more biochemistry values
01:48they are tall and so
01:50the more the patient can suffer from this disorder than in the more severe forms and truly believe me from a point of view
01:57extremely disabling and demanding from a medical point of view, both for the doctor and obviously for the patient but also for the doctor
02:05because we didn't have the tools we didn't have the therapies.
02:08Just as the tiredness, a particular tiredness that patients with primary biliary cholangitis suffer from is not only due to
02:17to the existence of primary biliary cholangitis but it is particular in the sense that not all patients have it
02:24the disease but when present has particular characteristics.
02:28There are many types of tiredness, let's call them that in English it is called fatiga, this one is described as having the
02:36batteries flat, this is the feeling you have from morning to afternoon to evening, you always have the feeling of
02:45have dead batteries.
02:48This type of tiredness that is described by patients was described to us a lot in the past too but we paid attention to it
02:57I repeat, less than we are used to considering it nowadays.
03:05Both in terms of more appropriate ways to evaluate it so it is not just the question that is asked during the visit
03:14outpatient clinic but tools are used which are questionnaires that investigate in a more adequate, more in-depth and more
03:23adequate these disorders.
03:25Here is the big news of the last few months and years: there are drugs capable of acting on
03:32these disorders and proof of this is all this great quantity of reports that were made during the last meeting
03:42American Association of Hepatology in the United States a few days ago where some data were presented not only
03:51on effectiveness in the short term but in the long term.
03:55Pen four years five years professor another interesting fact emerged from the study Ashur as you recalled also recalls the
04:06improvement of fatigue what do these results tell us in particular what prospects do they also open up for better management of
04:18symptoms for people with PPC.
04:21So in particular I would like to mention there have been several presentations in poster format in oral presentation format but there is
04:32It was a work that also aroused a lot of interest in the hepatological community present
04:40of a colleague from Texas Houston Marilyn Mayo who presented 48-month data on the capacity of a
04:55drug called Seladelpar to reduce starting from a basic data
05:03an index called NRS is an acronym but it is a more appropriate way of evaluating a scale that
05:16It tells us the degree of disturbance which can be mild, moderate, severe.
05:21So they studied it, they studied the effect, it reported an extremely positive effect in more than 50%
05:30of patients in the ability to reduce this score of this scale
05:36by as many as three points starting from a medium-high value, therefore not the very high values.
05:42And this is very interesting because let's say that the majority of patients today have a medium form of itching,
05:54so moderate, rather than severe.
05:56Then obviously there is the greatest interest in the severe ones but they are relatively few.
06:02On the other hand, those who are numerically more significant, the most significant numbers are those with mild and moderate forms.
06:10So the ability to intervene on this disabling disorder for patients, especially in this category,
06:19which are the group of patients in whom the progress of itching was monitored and observed for 48 months
06:32months, this is extremely interesting.
06:35Another one I want to mention is a study by another colleague, first in name but then the colleagues are
06:40always more or less the same
06:41which deal with these diseases, in the same centres, which always follow the same length, therefore observation, 4 years is
06:51a long period,
06:53demonstrated not only the correlation, that is, together with the progressive control correlation, reduction of this number in the NRS scale,
07:06also of the proportional values ​​of reduction of an interlucina, which is the interlucina 31, which has been found to be very connected
07:18at the itching levels
07:20and this is supported by the drug's ability to control, which is a pipar agonis, a nuclear receptor,
07:29which is acted upon by stimulating it and produces various effects, including itching.
07:37So the particular mechanism of action, the molecule that demonstrates the particular efficacy, here in the background,
07:45It must be said, despite many studies over a long time, the intimate, profound and mechanistic reason for itching,
07:54We don't know it yet, but the important thing is to be able to control it and this drug is evidently capable of doing that.
08:03do it.
08:04Professor, the efficacy and safety data of Seladel were also presented at the congress,
08:12After 5 years of treatment, what do these data tell us?
08:19They give us extremely important information, the data on one year, which was the study,
08:27the data called registration study, which allowed, in the face of evidence of efficacy and safety,
08:37to register the drug, here today they are strengthened because this efficacy evaluated in terms of control,
08:49reduction of biochemical, and therefore laboratory, indicators which indicate disease activity,
08:57it continues over time, as does the security, I repeat, demonstrated in the founding study,
09:06called registrants because these phase 3 studies allow the registration of drugs,
09:12Here we see that what was already observed in one year persists today well after 5 years,
09:20It's extremely positive and encouraging.
09:26Thank you

Consigliato